Introduction
Alzheimer's disease (AD) is the most common form of dementia among older people accounting for 60%e70% of all cases (World Health Organization and Alzheimer's Disease International, 2012). The disease is neuropathologically characterized by the presence of extracellular deposits of beta amyloid protein (Ab) in senile plaques, intracellular deposits of hyperphosphorylated tau protein in neurofibrillary tangles, dystrophic neurites, and by neuropil threads (Braak et al., 1998) . Besides the sporadic form of AD, for which aging is the main risk factor, mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) have been found to cause autosomal dominant early onset familial AD in a small number of families (Bertram and Tanzi, 2005) . The autosomal dominant form of AD is a very rare disorder with a prevalence less than 0.1% (Harvey et al., 2003) . Most mutations in these 3 genes result in alterations in the level of Ab in the brain and in the isoforms of Ab being produced, leading to Ab species with a higher propensity to aggregate. Introducing mutated forms of APP and PSEN1 individually or in combination into mice has led to the development of a variety of transgenic mouse lines that model aspects of Ab pathology (Wisniewski and Sigurdsson, 2010) . These mouse models have contributed significantly to our understanding of the molecular processes associated with plaque formation. It is, however, unclear whether the molecular alterations that cause plaque formation in models for familial AD also occur in nonfamilial, sporadic forms of AD. The suitability of current AD mouse models for studying sporadic AD therefore warrants further investigation.
We have recently performed a genome-wide gene expression study in the human prefrontal cortex during the progression of sporadic AD (Bossers et al., 2010a) . One of the most important findings was a concerted increase of genes involved in synaptic transmission and plasticity in nondemented individuals, in the preclinical stages of AD, just before the onset of plaque pathology in the prefrontal cortex. In parallel, we observed an increase in intraneuronal Ab levels. In contrast, after the development of the first plaques and tangles, the expression of these genes, which also include a group of genes involved in the generation and breakdown of Ab, sharply decreased. At the same time patients show memory impairments. Thus, we hypothesize that the initial increase in synaptic transmission and plasticity represents a compensatory reaction to the earliest Ab-related changes in AD.
Our gene expression data in AD provide the unique opportunity to examine whether similar changes in synaptic activity and plasticity can also be observed in Ab-based AD mouse models. We therefore have generated genome-wide expression profiles from the frontal cortex of APPswe/PS1dE9 transgenic mice (Jankowsky et al., 2004) and from their nontransgenic littermates throughout the entire progression of Ab pathology from 2 to 18 months of age. This double-transgenic mouse coexpresses APP695 with the Swedish mutation (K594M/N595L) and the human exon-9-deleted variant of PSEN1 and develops Ab plaques before 6 months of age (Jankowsky et al., 2004) . These mice also manifest memory deficits as early as the age of 2 months (Bonardi et al., 2011; Jankowsky et al., 2005; O'Leary and Brown, 2009; Pillay et al., 2008; Savonenko et al., 2005) .
Surprisingly, our gene expression data show that plaque formation and buildup in the frontal cortex of APPswe/PS1dE9 mice is solely associated with an increased expression of genes involved in an immune response and in glial activation, and in this brain region does not cause any changes in genes associated with memory, synaptic transmission, and plasticity.
Methods

Animals
In this study we used the double transgenic APPswe/PS1dE9 mouse, line 85 (Jankowsky et al., 2004) . For details see The Jackson Laboratory (strain B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J; stock number 004462; http://jaxmice.jax.org/). These animals express chimeric mouse/human APP695 with the Swedish mutation (K594M/N595L) and the human exon-9-deleted variant of PS1 (PS1dE9) under independent mouse prion protein promoters. AD mice were maintained as hemizygous and crossed with wild type (WT) C57BL/6. Genotyping was performed by real-time polymerase chain reaction (PCR) assays specific for the 2 transgenes and the prion promotor. All animals were housed under standard conditions with access to water and food ad libitum. For microarray and quantitative PCR (qPCR) experiments, 3 male and 3 female transgenic APPswe/PS1dE9 mice were used at each age (2, 3, 6, 9, 12 , and 15e18 months) studied. WT littermate mice served as age-and sexmatched control animals (2 male, 2 female per age group). For immunoblot analysis, additional APPswe/PS1dE9 mice at the age of 3 (n ¼ 2), 6 (n ¼ 3), 9 (n ¼ 1), and 18 (n ¼ 3) months were used. Immunohistochemistry was performed on animals also used for microarray, qPCR, or immunoblot studies. Animal handling and experimental procedures were reviewed and approved by the ethical committee for animal care and use of experimental animals of the Royal Netherlands Academy for Arts and Sciences, acting in accordance with the European Community Council directive of November 24, 1986 (86/609/EEC) . All efforts were made to minimize suffering and number of animals used for the study presented here.
Tissue harvesting
Animals were anesthetized with CO 2 /O 2 and decapitated. The gray matter of the right frontal cortex was isolated, snap-frozen in liquid nitrogen, and stored at À80 C for subsequent RNA or protein isolation. The left hemisphere was immersion fixed in phosphatebuffered 4% paraformaldehyde (PFA/PBS, pH 7.4) overnight at 4 C. After fixation the tissue was cryoprotected in phosphate buffered saline (PBS) containing 20% sucrose for a minimum of 5 hours at 4 C, embedded in Tissue-Tek (Sakura Finetek Europe, Alphen aan de Rijn, the Netherlands), frozen on dry ice, and stored at À80 C to be used for immunohistochemical analysis.
RNA isolation
RNA was isolated using a combination of TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA)-based and RNeasy Mini Kit (Qiagen, Hilden, Germany) RNA isolation methods. Briefly, frozen cortex tissue was homogenized in ice-cold 500 mL TRIzol and centrifuged at 12,000 g for 10 minutes. The supernatant was transferred to a new tube and vigorously mixed with 100 mL chloroform. Samples were loaded onto a Phase Lock Gel tube (5 Prime, Hamburg, Germany) and centrifuged at 12,000 g for 15 minutes. The aqueous phase was collected, mixed with an equal amount of 70% ethanol, applied to an RNeasy spin column and further processed according to the manufacturer's instructions. RNA was eluted in RNase-free water and stored at À80 C. RNA purity and yields were determined by a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). RNA integrity was determined by the RNA integrity number, as measured by the Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). The isolated RNA was of high integrity (average RNA integrity number 8.7, ranging from 7.3e9.5).
RNA labeling and microarray hybridization
For microarray analysis, the Whole Mouse Genome Microarray Kit with 4 Â 44000 probes was used (Agilent Technologies, Part Number G4122F). RNA labeling and microarray hybridization were performed according to the manufacturer's instructions. In short, for each sample 1 mg total RNA was linearly amplified and fluorescently labeled with either Cy3-or Cy5-cytosine triphosphate using the Agilent Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies). Before hybridization, equal amounts (825 ng) of Cy3-labeled and Cy5-labeled complementary RNA were mixed and fragmented in 1Â fragmentation buffer (Agilent Technologies) at 60 C for 30 minutes. The sample mix was hybridized to a microarray in 1Â Hi-RPM Hybridization Buffer (Agilent Technologies) at 65 C for 17 hours in a rotating hybridization chamber. A detailed description of all hybridizations for both the transgenic and wild type animals can be found in Supplementary Fig. 1 .
After hybridization, microarrays were washed in 6Â saline sodium phosphate-EDTA (SSPE)/0.005% N-Lauroylsarcosine for 5 minutes (Sigma-Aldrich, St. Louis, MO, USA), in 0.06x SSPE/ 0.005% N-Lauroylsarcosine for 1 minute and acetonitrile (Sigma-Aldrich) for 30 seconds, then dried in a nitrogen flow.
The microarrays were scanned with an Agilent DNA Microarray scanner at 100% photomultiplier tube setting and 5 mm resolution.
Microarray scans were quantified using Agilent Feature Extraction software (version 9.5.3).
Microarray normalization and single gene analysis
Raw expression data were analyzed in R statistical processing software (version 2.6.0) using the LIMMA package (Smyth, 2004) in Bioconductor (http://www.bioconductor.org). All features that were flagged as saturated or as a nonuniformity outlier by the feature extraction software on 1 or more arrays were excluded from further analysis. This was applicable for 2039 features, resulting in 39,136 features which passed these criteria. Data were normalized using LIMMA by applying a background correction (using the 'normexp' algorithm) followed by normalization of intensity distributions within and between arrays (using the 'quantile' algorithm). We have recently demonstrated that the analysis of the separate intensity channels (the individual Cy3 and Cy5 signals) yields more reproducible results than the standard ratio-based approach (the ratio between the Cy3 and Cy5 channels) for dual-color microarray datasets (Bossers et al., 2010b ), so we also applied this approach for the present dataset. Thus, the 2 log-transformed intensity measurements per sample were extracted from the normalized ratio data and used in all following analyses.
To detect genes with a significant interaction between age and genotype, we performed a 2-way analysis of variance (ANOVA) using age and genotype as grouping factors. The BenjaminieHochberg method was used to correct for multiple testing. p-values < 0.05 after correction were considered significant. A separate analysis for differences between genotypes in each age group using Student t tests revealed very similar differentially regulated genes as the ANOVA and is, therefore, not further considered here.
Cluster analysis of gene expression profiles
To follow the expression of individual transcripts over time we constructed time profiles of each transcript per genotype. Specifically, for each transcript, mean expression values for each age group were determined by averaging the individual intensity measurements. Expression values were normalized against the mean expression of all 2-month-old animals. Cluster analysis was performed to detect groups of transcripts with similar expression profiles (fuzzy clustering with the Mfuzz package, version 2.6.1 in Bioconductor). The fuzziness parameter M was determined by optimizing the detection of clusters as described in the Mfuzz manual, resulting in an M value of 1.3 that was used for further analysis. The microarray expression dataset was clustered into 8 separate clusters that allowed for the detection of small differences in expression profiles between gene clusters.
GO analysis of gene clusters
To gain insight into the biological functions that are associated with the gene clusters, overrepresented Gene Ontology (GO) classes associated with these clusters were determined with the GoStat program (http://gostat.wehi.edu.au) (Beißbarth and Speed, 2004) , using all genes on the array as a background dataset. GoStat output was corrected for multiple testing with the BenjaminieHochberg method. The first 30 GO classes with a p value < 0.001 which contained more than 5 genes, for which at least 1 gene was represented in the cluster under investigation, are presented in the final results (Table 2 ). GoStat does not allow for an evaluation of whether a significant 'parental branch' can be solely explained by its children.
Ingenuity pathway analysis of regulated genes
We performed a pathway analysis for all genes from cluster 4 and 8 (the clusters that showed a strong expression regulation over time). Ingenuity Pathway Analysis software (version 7.6; Ingenuity Systems, Mountain View, CA, USA) was used to identify direct and indirect physical and/or functional interactions between genes and/ or their protein products. To keep the results relevant for Ab deposition and AD related processes we included only significantly enriched canonical pathways in the final results table which were not related to a specific disease and contained at least 3 molecules.
Real-time qPCR confirmation
All qPCR experiments were performed on the same animals that were used for the microarray study. The time points 2, 3, 6, 9, 12, and 15e18 months were evaluated. For each sample 1 mg total RNA was reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer's protocol. As negative control, samples of each batch of reverse transcription were pooled and incubated with primer mix lacking reverse transcriptase. The obtained cDNA was stored at À20 C until use. Primers were designed using Primer3 (http://frodo.wi.mit.edu) (Rozen and Skaletsky, 2000) . Primer sequences are listed in Supplementary  Table 1 . For each primer pair, dissociation curves were generated to assess specificity. Only single products and no primer dimers were detected. Each qPCR reaction contained 1.5 mL 2 mM primer solution, 5 mL SYBR Green Master mix (Applied Biosystems) and 2.86 ng cDNA in a 10 mL reaction volume. The reaction was run at default settings (95 C, 15 seconds; 60 C, 1 minute; 40 cycles) on the ABI Prism 7300 sequence detection system (Applied Biosystems). Samples were normalized to the housekeeping genes 28S, Gapdh, and b-actin that are not regulated between different ages in the mice used. Normalization factors were determined using the GeNorm (Vandesompele et al., 2002) VBA applet (version 3.5) for Microsoft Excel.
Immunohistochemistry
Ten-mm cryostat sections were mounted on Superfrost Plus slides (Thermo Scientific Menzel, Braunschweig, Germany). Sections were stored at À80 C or À20 C until use. Cryosections were dried for 15 minutes and fixed in 4% PFA/PBS (pH 7.4) for 3 minutes. Antigen retrieval was performed in 10 mM sodium citrate (pH 6.0)/0.05% Tween-20 for 20 minutes at 95 C. For the immunohistochemical detection of Ab, an additional pretreatment with 70% formic acid for 10 minutes was performed. Sections were then blocked with 10% fetal calf serum (FCS) in PBS/0.4% Triton-X 100 for 1 hour at room temperature. Thereafter, sections were incubated with monoclonal antibody 4G8 (Signet Laboratories, Dedham, MA, USA; 1:10,000) in PBS/0.4% Triton-X 100 for 1 hour at room temperature. Next, sections were incubated with biotinylated horse anti-mouse antibody (Vector Laboratories, Burlingame, CA, USA; 1:400) in PBS/1% FCS for 1 hour at room temperature. Sections were incubated in ABC solution (Vector Laboratories) for 1 hour at room temperature, followed by a 5-minute incubation with 3,3'-diaminobenzidine as chromogen. Sections were dehydrated in a graded ethanol series followed by xylene and embedded with entellan glue. For quantification of Ab load, tiled photographs of the whole section were taken with a XC-77CE CCD monochrome camera (Sony, Badhoevedorp, The Netherlands) through a 10Â objective connected to an Axioskop microscope (Zeiss, Jena, Germany). Analysis of the cortex area covered with Ab plaques was done using the Image-Pro Plus software (version 6.0, Media Cybernetics, Bethesda, MD, USA) with a computer-generated mask manually overlaid on the cortex, which recognized 3,3'-diaminobenzidine staining. Plaque load was evaluated in all animals used for the microarray and qPCR studies.
For immunofluorescent stainings of glial-fibrillary acidic protein (GFAP), allograft inflammatory factor 1 (IBA1), and complement component 4b (C4B), cryostat sections of 3-and 15e18-month-old animals were used (4 transgenic animals per age group: 4 males at 3 months, 2 males and 2 females at 15e18 months; 2 WT male animals per age group). Tissue from 6 transgenic animals and the WT animals were also used in the microarray study; tissue from 2 transgenic animals was used in the immunoblot experiments. Fixation and retrieval were performed as described above. Primary antibodies were rabbit anti-C4B (Abcam, Cambridge, UK; 1:300), rabbit anti-IBA1 (Wako Chemicals, Neuss, Germany; 1:600) and rabbit anti-GFAP (Dako, Glostrup, Denmark; 1:2000) in PBS/0.4% Triton-X 100/3% FCS overnight at 4 C. Cy3-conjugated donkey anti rabbit IgG (Jackson Immuno Research, Newmarket, Suffolk, UK; 1:1000) in PBS/0.4% Triton-X 100/1% FCS was used as secondary antibody for 2 hours at room temperature. Ab plaques were visualized with 0.0125% thioflavine S in 50% ethanol for 10 minutes. Sections were then treated with Hoechst (Invitrogen; 1:20,000) in PBS for 10 minutes to visualize cell nuclei and mounted with Mowiol embedding medium. Photographs were taken using an Axioplan 2 fluorescent microscope (Zeiss) connected to an MP digital camera (MediaCybernetics) with a 20Â objective.
Western blot analysis
The frozen right hemisphere cortex samples were homogenized in suspension buffer (0.1 M NaCl, 0.01 M Tris-HCl, 0.001 M ethylenediaminetetraacetic acid) containing protease inhibitors (20 mM antipain, 1 mM pepstatin, 20 mM chymostatin, 10 mg/mL leupeptin, and 100 mg/mL phenylmethanesulphonylfluoride) using an ultra turrax tissue homogenizer. Homogenates were centrifuged at 14,000 rpm for 5 minutes at 4 C, the supernatant was collected and protein concentrations were measured using a bicinchoninic acid protein assay kit (Pierce, Thermo Scientific, Rockford, IL, USA). Immunoblotting experiments were performed for GFAP, C4B, and IBA1 using the same antibodies as for the immunostainings. For each sample, 26.8 mg protein was heated in 5Â loading buffer containing 10% sodium dodecyl sulphate and 10% b-mercaptoethanol at 95 C for 10 minutes. Tris-glycine sodium dodecyl sulphate polyacrylamide gel electrophoresis was performed using the BioRad Mini-PROTEAN 3 gel electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA). Gels contained 8% (C4B), 12% (GFAP), and 15% (IBA1) acrylamide/bisacrylamide. Proteins were transferred to nitrocellulose membranes using a semidry (GFAP and IBA1) or wet (C4B) blotting procedure and blocked with 5% fat-free milk powder in PBS/0.05% Tween-20 for 1 hour at room temperature. Blots were incubated with antibodies against GFAP, C4B (diluted in PBS/0.05% Tween-20/5% milk) or IBA1 (diluted in supermix: 0.25% gelatin, 0.5% Triton-X 100 in PBS, pH 7.4) for 2 hours at room temperature or 4 C overnight. b-actin (Sigma-Aldrich; 1:2000) was used as a loading control. Primary antibodies were detected with an IR800 antibody (Rockland Immunohistochemicals, Gilbertsville, PA, USA; 1:5000) and b-actin was detected with a Cy5-conjugated antibody (Jackson Immuno Research; 1:2000) for 2 hours at room temperature. Blots were scanned and analyzed using the Odyssey Infrared Imager and Odyssey 2.1 scanning software (LI-COR Biosciences, Lincoln, NE, USA). The b-actin signal was used to normalize the final protein quantifications.
Results
Ab plaque pathology in APPswe/PS1dE9 mice increases with age
We first confirmed the previously documented plaque pathology in our mouse colony. Immunohistochemical detection of Ab, using the 4G8 antibody, in brain sections of the APPswe/PS1dE9 transgenic mice showed that Ab plaque load in the frontal cortex increased with age ( Fig. 1 ). The first plaques were detected at the age of 6 months. This is in good agreement with earlier reports showing that these mice show plaques from very early in age (Garcia-Alloza et al., 2006; Jankowsky et al., 2004; Kamphuis et al., 2012; Ruan et al., 2009) . As the plaque load in the frontal cortex of APPswe/PS1dE9 mice did not change between 15 and 18 months of age (3.61 AE 0.5% vs. 3.65 AE 1.2%; p > 0.05), we combined these 2 age groups for the gene expression analysis. Fig. 1 . Beta amyloid protein (Ab) plaque pathology increased with age in APPswe/PS1dE9 mice. (A) Ab plaques were stained with the monoclonal anti-amyloid 4G8 antibody on the left hemisphere of the frontal cortex. First plaques were detected at 6 months of age and plaque burden increased with age. A representative example picture of a 2-month-old wild type mouse cortex (upper left), is shown together with representative examples from APPswe/PS1dE9 transgenic mice at the age of 2, 3, 6, 9, 12, 15, and 18 months. Scale bar: 0.2 mm. (B) Quantification of plaque load in the frontal cortex of APPswe/PS1dE9 and wild type mice for all age groups (n ¼ 6 per group). Plaque load is represented in percentage of the frontal cortex area that is covered with plaques. The increase of plaque load over time is significant (analysis of variance; p < 0.001). Wild type animals do not show increased plaque load with age and are pooled for the quantification. Abbreviations: TG, transgenic; WT, wild type.
Microarray analysis of gene expression: upregulation of genes coincides with plaque development
To determine the gene expression changes that are specifically associated with Ab pathology, microarrays were used to assess the transcriptional alterations that occur during the development of plaque pathology in the frontal cortex of APPswe/PS1dE9 mice, and we compared these with age-related gene expression changes in agematched wild type littermates. A total of 87 transcripts showed a significant interaction between age and genotype (ANOVA-based p value < 0.05, Table 1 ). All significantly regulated transcripts were upregulated over time. No genes were detected that showed a transcriptional downregulation with age and plaque development. Among the significantly upregulated genes were many genes involved in the regulation of immune function such as a large group of Cluster of differentiation (Cd) antigens (Cd9, Cd14, Cd48, Cd52, Cd68, Cd84, Cd86, Cd180, Cd300d, Cd300lf, Fcgr2b, Fcgr3, Itgax, Lair1, Lilrb4, Pdcd1, Siglecf, Tlr2, Tnfsf13b), chemokine ligands (Ccl3, Ccl4, Ccl6, Cxcl5), and members of the complement system (C1qc, C4b). The microglia marker allograft inflammatory factor 1 (Aif1/ Iba1) and the astrocyte marker glial fibrillary acidic protein (Gfap) were 2.2-and 7.9-fold upregulated, respectively. Furthermore, we found genes involved in lipid metabolism (Apobec1, Apoc4, Ch25h, Lpl) and cathepsins (Ctsc, Ctsh, Ctsz) to be upregulated.
Next, we performed a cluster analysis on the expression profiles of all genes over time in both the APPswe/PS1dE9 transgenic animals and in wild type controls to detect groups of genes with concerted patterns of expression. In the APPswe/PS1dE9 mouse, this cluster analysis revealed 2 clusters (4 and 8) in which transcripts showed an upregulation starting between 3 and 6 months of age; coinciding with the development of Ab plaque pathology ( Fig. 2A) . Cluster 8 contained the transcripts with the highest fold changes. Transcripts in cluster 4 also showed a continuous upregulation over time but with lower fold changes. Before the onset of plaque pathology, at the 2-and 3-month time points, no gene regulation was detected. Clusters of transcripts of wild type animals did not show any significant changes in their time profile (data not shown).
We selected a set of 17 regulated genes (Bcl3, synaptogyrin 1 [Syngr1], Baiap2l2, Birc1b, activating transcription factor 3 [Atf3], Itgax, Pdcd1, Ccl6, Gpr109a, Tlr2, Trem2, Iba1, Tyropb, Cd9, Bcl2a1b, Igf1, Gfap) to validate the microarray data using qPCR. For all selected genes the patterns of gene expression over time were highly correlated between the microarray and qPCR measurements (R 2 ! 0.96; p < 0.001; example plots see Fig. 2B ) for the APPswe/ PS1dE9 mice. Furthermore, fold change between APPswe/PS1dE9 and wild type at 15e18 months as measured by qPCR showed a strong linear correlation with the microarray-derived fold change at that same time point (R 2 ¼ 0.85; p < 0.001; Fig. 2C ).
Functional annotation and pathway analysis: immune response is induced after plaque formation
To investigate which biological processes were associated with the upregulated genes in APPswe/PS1dE9 mice, we performed a GO overrepresentation analysis on the upregulated clusters 4 and 8. This analysis revealed that these clusters were highly enriched for transcripts involved in immune response-associated processes, such as the biological process GO classes 'immune system process,' 'defense response,' 'response to external stimulus,' and 'response to wounding and inflammatory response' (see Table 2 for the 30 most significant GO identifiers and Supplementary Table 3 for the full list of overrepresented pathways). The results of the Ingenuity Pathway analysis and GO analysis were thus in general agreement with each other.
IBA1, GFAP, and C4B protein levels corroborate the gene expression data
Gene expression data indicated an immune and glial response in APPswe/PS1dE9 mice including the upregulation of Iba1, Gfap, and complement component 4b (C4b). We therefore studied whether microgliosis, astrogliosis, and inflammation were also present on the protein level using antibodies against IBA1, GFAP, and C4B, respectively. Analysis of the immunoreactivity levels revealed that IBA1, GFAP, and C4B protein were highly upregulated in the frontal cortex of APPswe/PS1dE9 mice at 15 months of age (when plaques were abundantly present) compared with age-matched wild type animals without plaque pathology (Fig. 3A) . GFAP staining was observed in activated astroglia distributed uniformly over the frontal cortex while and IBA1 immunoreactivity was clearly detectable in activated microglia around plaques. C4B staining was strongly visible in microglia forming an outer rim around the plaques. To quantify protein expression levels, we performed Western blot analysis of IBA1, GFAP, and C4B in the frontal cortex of APPswe/PS1dE9 mice (Fig. 3B) . Quantification of the immunoblots revealed that GFAP and IBA1 protein expression significantly increased over time (ANOVA, p < 0.05). We observed a mild, but nonsignificant, increase of C4B protein expression (ANOVA, p ¼ 0.5; p ¼ 0.28 when an outlier was removed). Wild type animals did not show significant changes in protein expression of GFAP, IBA1, and C4B over time (data not shown).
Plaque formation is not associated with transcriptional alterations of genes involved in synaptic activity or plasticity
Changes in synaptic transmission and plasticity related genes occur early in AD patients in Braak stages 2 and 3 (Bossers et al., 2010a) . However, in APPswe/PS1dE9 mice the analysis of differential gene expression and the GO analysis did not reveal transcriptional alterations in genes that have a function in synaptic activity or plasticity during Ab plaque formation. To confirm that key synaptic genes were indeed not regulated in APPswe/PS1dE9 mice we performed an extensive qPCR analysis for the time points 2, 3, 6, 9, 12, and 15e18 months. The selection of synaptic genes was based on 2 criteria. First, 14 genes were selected that have been investigated in another very similar APPþPS1 mouse model for AD (Dickey et al., 2003; see Fig. 4 and Supplementary Table 1 for a specification of the studied genes and primer sequences). Seven of those genes were reported to be downregulated. Like the APPswe/PS1dE9 mouse, the APPþPS1 mouse carries the Swedish mutation of APP (K670N, M671L), but a different PS1 mutation (M146L) (Holcomb et al., 1998) . Second, 9 genes were selected because these have been shown to be regulated in a recent microarray study in human postmortem prefrontal cortex tissue of AD patients (Bossers et al., 2010a) . The qPCR analysis showed that only 3 wellstudied synaptic genesdearly growth response 1 (Egr1), activity regulated cytoskeletal-associated protein (Arc), and nuclear receptor subfamily 4, group A, member 1 (Nr4a1)dshowed a trend These 3 genes were also reported to be downregulated in the study by Dickey and colleagues (2003) . None of the other synaptic genes, including those that were found to be changed in the human data set, showed alterations in mRNA expression. Importantly, for all of the genes, the qPCR data corroborated the APPswe/PS1dE9 microarray results.
APPswe/PS1dE9 and human AD data show very limited overlap
To further investigate the similarities and differences between gene expression changes in the APPswe/PS1dE9 mouse and the human AD brain, we performed a qPCR study on 8 genes (Bcl2, Btg1, Cd59, Gtf2i, Mxi1, Slc6a12, Cycs, Chchd2) that we have found to be consistently regulated in at least 3 out of 5 published human AD microarray data sets (Blalock et al., 2004; Bossers et al., 2010a; Emilsson et al., 2006; Parachikova et al., 2007; Xu et al., 2006) . None of these genes showed a significant regulation of expression in the APPswe/PS1dE9 mouse model at 2, 3, 6, 9, 12, and 15e18 months of age. However, the Bcl-2 like gene Bcl2a1b was significantly upregulated on the mouse microarray.
We also investigated whether transcriptional changes that occurred in APPswe/PS1dE9 mice with developing plaque pathology were comparable with gene expression changes in the human brain during the progression of sporadic AD (Bossers et al., 2010a) . This data set contains gene expression data of the gray matter of the prefrontal cortex before and after plaque development and a comparison with the APPswe/PS1dE9 data set might thus elucidate whether transcriptional changes associated with Ab plaque development in the mouse are similar to the human situation. The analysis of the overlap between the lists of significantly regulated genes in the APPswe/ PS1dE9 data set (n ¼ 87 genes) and the human data set (n ¼ 922 genes) revealed that only 3 genes (solute carrier family 14 [urea transporter] member 1 [Slc14a1], C4b, plexin domain containing 2 [Plxdc2]) were significantly upregulated in both the mouse and human data sets with increasing plaque load or Braak stages, respectively.
A comparison of the overrepresented biological process GO classes in the 2 data sets also revealed a minimal overlap between mouse and human data. The mouse clusters were associated with immune response. In the human AD brain, however, the clusters of downregulated genes are associated with synaptic activity and plasticity and the clusters with upregulated genes are associated with transcription, metal ion binding, differentiation/proliferation and, as small overlap with the mouse data, antigen processing (Bossers et al., 2010a) . Comparing only the immune responserelated clusters in the APPswe/PS1dE9 mouse and sporadic AD data, we found that C3, C4B, CXCL10, CXCR4, histocompatibility 
Discussion
In the present study we used microarray technology to examine which transcriptional changes occur in the frontal cortex of the double-transgenic mouse line APPswe/PS1dE9 before, during, and after the development of dense-core Ab plaques and to compare these transcriptional alterations to transcriptional changes in the human AD brain. Only a limited number of studies have explored genome-wide transcriptional changes at 2 or 3 time points during the development of Ab plaques in AD mouse models: in the cerebral cortex (Reddy et al., 2004) , and the Tg2576/PS P264L/þ mouse , and the hippocampus and cortex of the PDAPP (APP V717 ) mouse (Selwood et al., 2009 ). The results from these experiments were remarkably diverse and included the upregulation of apoptotic genes (Reddy et al., 2004) , the upregulation of genes involved in mitochondrial energy metabolism (Reddy et al., 2004) , the upregulation of carbohydrate metabolism and proteolysis , the downregulation of transcription and translation (Selwood et al., 2009) , the upregulation of immune response related genes and the downregulation of genes involved in neuronal survival (Selwood et al., 2009; Wu et al., 2006) . These studies investigated genome-wide patterns of gene expression at 2 or 3 time points throughout the progression of Ab pathology. However, they focused only on either intermediate stages (Selwood et al., 2009) , or early and late stages (Reddy et al., 2004; Wu et al., 2006) of the plaque pathology. In the current study we investigated the whole time profile from 2 to 18 months to monitor closely the transcriptional changes that occur before and during the buildup of Ab pathology.
To follow the expression of individual transcripts during the development of Ab plaque pathology, we constructed expression profiles over time. This approach revealed 2 clusters of concerted Age data are presented as 2 log-transformed fold change against average of all 2-month-old animals (wild type and transgenic). p values are BenjaminieHochberg corrected ANOVA values. Fold change ¼ maximum fold change between age groups. Cluster ¼ cluster assignment (see Figure 2 ). All genes with p < 0.05 are listed. Abbreviations: mRNA, messenger RNA; Mo, months.
upregulated genes over the progression of plaque pathology with pronounced transcriptional changes detected from the age of 6 months onward, suggesting a link between the development of plaque pathology and transcription of these genes. However, because we have not investigated time points in between 3 and 6 months, we cannot further specify whether gene upregulation starts shortly before, shortly after, or at the same time as the appearance of the first plaques.
Plaque development in APPswe/PS1dE9 mice is accompanied by astroglial and microglial activation
We compared the significantly regulated genes of our data set with transcriptome databases for genes enriched in astrocytes, oligodendrocytes, neurons (Cahoy et al., 2008) , and microglia (Thomas et al., 2006) to investigate whether those genes, whose expression is induced at the time that Ab pathology becomes apparent in the cortex of the APPswe/PS1dE9, are expressed in a particular cell type. The great majority of significantly regulated genes were expressed in microglia (53 genes: Afp, Aif1, Apbb1ip, Apobec1, Arpc1b, Asb10, Atf3, B2m, Bcl3, Birc1b, Btk, Ccl3, Ccl4, Ccl6, Cd14, Cd48, Cd52, Cd68, Cd84, Cd86, Cd9, Cst7, Ctsc, Ctsh, Ctsz, Ebi2, Fcgr2b, Fcgr3, Gpnmb, Gpr65, Gusb, Igf1, Itgax, Klhl6, Lair1, Lilrb4, Lpl, Lrmp, Ly86, Mamdc2, Mpeg1, Pon3, Rnase4, Rnaset2, Samsn1, Slc11a1, Slc15a3, Spp1, Syngr1, Tlr2, Tnfsf13b, Trem2, Tyrobp) . Twenty of the significantly regulated genes (Atf3, AU020206, B2m, Bcl2a1b, C4b, Cd14, Cnn3, Ctsc Ctsz, Cybrd1, Frrs1, Gfap, Gusb, Lair1, Mamdc2, Osmr, Plxdc2, Ptx3, Rnaset2, Slc14a1) were at least 1.5-fold enriched in astrocytes, with 3 (Cybrd1, Gfap, Slc14a1) being astrocyte-specific. It should be noted, however, that we found C4B protein expression in microglia and not in astrocytes. Only 4 significant genes were enriched in neurons (Ccl4, Igf1, Lpl, Syngr1). None of the regulated genes was enriched in oligodendrocytes. The upregulation of many microglia genes including Cd68, a marker for activated microglia, indicates an activation of microglia by Ab. This is in line with other studies reporting that IBA1 positive microglia express CD68 in AD mouse models (Bornemann et al., 2001; Kamphuis et al., 2012) . Activated microglia are an effective response for the elimination of pathogens and are thought to mediate the degradation and clearance of Ab (Boissonneault et al., 2009; Chen et al., 2006) . Furthermore, the upregulation of many genes expressed in astrocytes indicates a clear involvement of astrocytes in Ab pathology. Indeed, astrocytes are able to degrade Ab (Wyss-Coray et al., 2003) and play an important role in the induction of neuroinflammation in AD (Li et al., 2011) . Overall, our findings support earlier reports that astroglia become hypertrophic and that microglia tend to accumulate in and around senile plaques, both in animal models and in AD patients (Johnston et al., 2011; Kamphuis et al., 2012; Olabarria et al., 2010) and that they exhibit an activated phenotype (Yan et al., 2009) leading to the activation of host defense mechanisms.
APPswe/PS1dE9 mice exhibit a well-controlled immune response
Glial activation leads to the production of pro-and antiinflammatory cytokines (Hanisch and Kettenmann, 2007; Li et al., 2011) . Indeed, the great majority of upregulated transcripts in the APPswe/PS1dE9 mouse was involved in immune system related processes, including many Cd antigens, chemokine ligands, and members of the complement system. In contrast to earlier reports (Hickman et al., 2008; Ruan et al., 2009) , our data show that in APPswe/PS1dE9 mice well-known proinflammatory mediators (Il-1, Il-6, tumor necrosis factor a [Tnfa] , interferon g, and Tgfß)
were not significantly increased. Instead, we observed a strong upregulation of immune suppressive mediators like polypeptide growth factor 1 (Igf1) and triggering receptor expressed on myeloid cells 2 (Trem2). The production of proinflammatory cytokines such as Tnfa might be suppressed by the upregulation of Fc receptor gamma 2b (Fcgr2b) (Smith and Clatworthy, 2010) , Igf1 (Gasparini and Xu, 2003) , Trem2 (Frank et al., 2008; Melchior et al., 2010) , and programmed cell death 1 (Pdcd1) (Yao et al., 2009) , molecules that have been indicated to decrease the severity of (auto)immune responses and to promote neuroprotective immune responses. As Tnfa, together with interferon g, also stimulates Ab deposition by inducing the production of Ab peptides and decreasing the secretion of soluble APPs (Blasko et al., 1999) , the successful reduction of Tnfa is, therefore, a frequently investigated therapeutic strategy for AD patients (Frankola et al., 2011; Park and Bowers, 2010) . The APPswe/PS1dE9 mouse with its naturally occurring inhibition of Tnfa upregulation could possibly help to understand better which genes contribute to low Tnfa levels. Furthermore, our data suggest that the upregulation of Atf3 in APPswe/PS1dE9 mice might serve as a control mechanism to limit the amount of Ccl4 (Khuu et al., 2007) and to inhibit Tlr2-stimulated inflammatory responses (Gilchrist et al., 2006; Liu et al., 2012; Sabroe et al., 2005 ). An excessive immune response might also be prevented by the upregulation of interferon regulatory factor 8 (Irf8) which negatively regulates MHC Class I molecules (Agrawal and Kishore, 2000) . In general, our data suggest that Ab invokes a well-controlled immune response to buildup rather than a strong inflammatory response in APPswe/PS1dE9 mice.
4.3. The expression of genes involved in synaptic function and plasticity is not altered in APPswe/PS1dE9 mice cortex In our microarray and qPCR studies, we did not observe any significant transcriptional changes of genes with synaptic function in the APPswe/PS1dE9 mice. We observed only a single significantly upregulated gene, Syngr1, with reported synaptic function. Syngr1 is essential for short-and long-term potentiation in the hippocampus and it inhibits Ca 2þ -dependent exocytosis (Sugita et al., 1999) . Syngr1 is localized to the membrane of small presynaptic vesicles (Kedra et al., 1998) and facilitates the targeting of synaptophysin to synaptic-like microvesicles in PC12 cells (Belfort and Kandror, 2003) , a model system for synaptic vesicles. However, a study in human postmortem tissue showed that Syngr1 is downand not upregulated in late onset AD patients (Liang et al., 2010) .
Igf1 and Tlr2 are both strongly upregulated in the APPswe/ PS1dE9 mice. In addition to their role in the immune system they have been implicated in neuronal functioning. Igf1 has neuroprotective effects and promotes neurogenesis, development, differentiation, synapse formation, and glucose utilization throughout the brain (Torres-Aleman, 2000) . Furthermore, IgfI enhances cognitive performance, increases the levels of synaptic proteins (Carro et al., 2006) , and reverses Ab-induced neurotoxicity (Jarvis et al., 2007) . In humans, IGF1 plasma levels are reduced in familial AD patients (Mustafa et al., 1999) and in aged subjects (Arvat et al., 2000) . Tlr2 is involved in adult neurogenesis (Rolls et al., 2007) . APP-PS1-Tlr2(-/-) mice show accelerated cognitive impairments paired with increased Ab levels and Tlr2 treatment in these mice had beneficial effects by restoring the memory consolidation process (Richard et al., 2008) . In humans, a polymorphism in Tlr2 changes the susceptibility to AD in a Chinese population . It is possible that the upregulation of Igf1 and Tlr2 helps to prevent neuronal damage in the frontal cortex of APPswe/PS1dE9 mice.
It has been suggested that amyloid might suppress molecular mechanisms for memory, independent of neuron or synapse loss (Dickey et al., 2003 (Dickey et al., , 2004 . However, Egr1, Arc, and Nr4a1, 3 immediate-early genes associated with long-term potentiation and memory consolidation, were the only genes associated with memory that showed a nonsignificant, decrease in the cortex of aged APPswe/ PS1dE9 mice. This decrease was comparable with the decrease in the cortex and hippocampus of another APPþPS1 mouse model reported by Dickey and colleagues.
It is noteworthy that some studies show cognitive deficits in APPswe/PS1dE9 mice as early as 2e3 months (Pillay et al., 2008) , 4 months (Bonardi et al., 2011) , and 5 months (Timmer et al., 2010) of age. A larger body of evidence shows cognitive deficits at 6 months (Filali and Lalonde, 2009; Jankowsky et al., 2005; Kilgore et al., 2010; Lagadec et al., 2012; Minkeviciene et al., 2008) with the exception of a single study that could not detect cognitive deficits at that time point . Other studies have only investigated later time points and have consistently found cognitive deficits in older APPswe/PS1dE9 mice (Gimbel et al., 2010; Hooijmans et al., 2009; Melnikova et al., 2006; O'Leary and Brown, 2009; Toledo and Inestrosa, 2010) . Most relevant to the cortical gene expression data presented here, Filali and Lalonde (2009) demonstrated that 6-month-old APPswe/PS1dE9 mice show deficits in nest building, which is indicative for prefrontal cortex dependent step-by-step planning and organization. Our transcriptional profiling data suggest that frontal cortex-dependent cognitive deficits in APPswe/ PS1dE9 mice are not because of transcriptional changes of genes involved in learning and memory in cortical neurons. Because behavioral alterations can be caused by neuroinflammation (Arnaud et al., 2006; Fan et al., 2007; Labrousse et al., 2012; Zhang et al., 2012) , the robust cognitive deficits in the APPswe/PS1dE9 mice starting at 6 months might partly be the result of changes in the expression of genes that govern an immune reaction. It should be noted that gene expression changes in other brain areas, such as the hippocampus, are very likely to contribute to frontal cortexindependent behavioral deficits.
APPswe/PS1dE9 mice transcriptional profiles do not resemble human AD data
In the present study we compared transcriptional changes in the frontal cortex of APPswe/PS1dE9 mice and AD patients during the development of AD pathology. In the human sporadic AD brain we observed that the appearance of AD neuropathology in Braak stage Gene expression of well-known synaptic genes that were investigated in another, but similar APP-PS1 transgenic mouse model (Dickey et al., 2003) or found to be regulated in human AD patients (Bossers et al., 2010a) was studied in APPswe/ PS1dE9 mice using quantitative polymerase chain reaction (qPCR). Note that only Nr4a1, Arc, and Egr1 are mildly downregulated (not significant).
3 is preceded by transcriptional changes in genes related to neuronal plasticity and activity in Braak stage 2 (Bossers et al., 2010a) . We have not observed any evidence for changes in genes involved in these processes in the APPswe/PS1dE9 mouse. When comparing gene expression changes in end-stage AD patients (Braak stages 5 and 6) and aged APPswe/PS1dE9 mice, only 3 genes (Plxdc2, Slc14a1, and C4b) showed a significant regulation in both the transgenic APPswe/PS1dE9 mice and the sporadic human AD data sets. Blood-group antigen Slc14a1, an erythrocyte urea transporter, has so far no clear function in the nervous system (Bagnasco, 2006) . Plxdc2 has been shown to coordinate cell proliferation and differentiation in the developing nervous system (Miller-Delaney et al., 2011) and in cancer (Carson-Walter et al., 2001; Davies et al., 2004; Rmali et al., 2007) . Our finding that both genes are upregulated in an AD mouse model and in patients with Ab plaques might suggest a yet unknown function for these genes in Ab pathology. C4b, which is part of the classic activation pathway of the complement system, has been described to be highly expressed in and around plaques of the Arctic, Tg2576 (Fonseca et al., 2011) and APPþPS1 (Dickey et al., 2003) mouse models for AD and to prevent early stages of autoimmune disease (Paul et al., 2002) . These results, together with our findings, suggest that C4b plays a role in Ab-induced immune response.
In addition, we investigated whether genes that are consistently altered in multiple human AD microarray datasets (BCL2, BTG1, CD59, GTF2I, MXI1, SLC6A12, CYCS, and CHCHD2) (Blalock et al., 2004; Bossers et al., 2010a; Emilsson et al., 2006; Parachikova et al., 2007; Xu et al., 2006) are also altered in the APPswe/ PS1dE9 mouse. We found that none of these genes are significantly altered in the cortex of APPswe/PS1dE9 mice. It should be noted that APPswe/PS1dE9 mice carry mutations in the APP and the PSEN1 gene, though these genes are not mutated in sporadic AD patients. The molecular mechanisms leading to plaque formation and memory deficits in these mice and sporadic AD patients might therefore be substantially different.
Functional annotations of regulated gene clusters in the transgenic mouse model hardly overlap with human data (Bossers et al., 2010a) . Though the mouse only shows alterations in immunerelated genes, the development and progression of AD in the human prefrontal cortex is associated with many (early) changes regarding synaptic activity, plasticity, transcription, metal ion binding, differentiation, and proliferation. The APPswe/PS1dE9 mouse is therefore not suitable for studying these aspects of AD, especially early synaptic changes.
The APPswe/PS1dE9 mouse can be a model for AD-related immune response
Because we predominantly detected alterations in immunerelated transcripts in APPswe/PS1dE9 mice, we specifically investigated whether we could find commonalities between human AD and the APPswe/PS1dE9 mouse in the regulation of immunerelated transcripts other than the previously discussed genes TREM2 and C4B. Indeed, C3, CXCL10, CXCR4, HLA-DRB1, ICOSLG, IRAK3, KLHL6, RGS1, SERPINA3, and TGFB1 showed a trend toward upregulation in the cortex of the APPswe/PS1dE9 and the human AD data sets. Interestingly, most of these genes have been implicated in AD or amyloid pathology. Upregulation of the complement component C3 has been proposed to reduce Ab plaque burden and neuronal loss by modulating microglia toward a classic M1-like activated phenotype (Maier et al., 2008) and activates Cd68. C3 upregulation itself is a result of anti-inflammatory Tgfb1 upregulation (Wyss-Coray et al., 2002) . Tgfb1 also upregulates Irak3, a negative regulator of Toll-like receptor signaling (Standiford et al., 2011) . The chemokine ligand CXCL10 is increased in brains of AD mouse models (Duan et al., 2008; Israelsson et al., 2010) and in cerebrospinal fluid of patients with mild AD (Galimberti et al., 2006) , and chemokine receptor CXCR4 is downregulated in the Tg2576 mouse model for AD, but upregulated in AD patients (Parachikova and Cotman, 2007) . The major HLA-DRB1 is expressed in antigen presenting dendritic cells and HLA-DR alleles might account for differences in Ab-reactive T cells and Ab immunogenicity (Zota et al., 2009) . Polymorphisms in SERPINA3 have been implicated to modify the risk for AD associated with the apolipoprotein E ε4 allele (DeKosky et al., 1996; Kamboh et al., 1995 Kamboh et al., , 2006 .
Inflammation is a key contributing factor in the pathology of AD and many hallmarks of neuroinflammation (such as activation of microglia and the complement system, increased cytokine expression) are observed in tissue of AD patients (Eikelenboom et al., 2010 (Eikelenboom et al., , 2011 Frank-Cannon et al., 2009) . Studying the immune response in AD is therefore essential for understanding the disease and developing therapies. Our study in the APPswe/PS1dE9 mouse model has uncovered the full temporal profile of transcriptional changes in immune genes that are associated with Ab pathology, and provides a valuable resource to further elucidate the Abinduced immune response in AD.
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